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Abstract The poor heating efficiency of the most
reported magnetic nanoparticles (MNPs), allied to the
lack of comprehensive biocompatibility and haemo-
dynamic studies, hampers the spread of multifunc-
tional nanoparticles as the next generation of
therapeutic bio-agents in medicine. The present work
reports the synthesis and characterization, with special
focus on biological/toxicological compatibility, of
superparamagnetic nanoparticles with diameter
around 18 nm, suitable for theranostic applications
(i.e. simultaneous diagnosis and therapy of cancer).
Envisioning more insights into the complex nanopar-
ticle-red blood cells (RBCs) membrane interaction,
the deformability of the human RBCs in contact with
magnetic nanoparticles (MNPs) was assessed for the
first time with a microfluidic extensional approach,
and used as an indicator of haematological disorders in
comparison with a conventional haematological test,
i.e. the haemolysis analysis. Microfluidic results
highlight the potential of this microfluidic tool over
traditional haemolysis analysis, by detecting small
increments in the rigidity of the blood cells, when
traditional haemotoxicology analysis showed no sig-
nificant alteration (haemolysis rates lower than 2 %).
The detected rigidity has been predicted to be due to
the wrapping of small MNPs by the bilayer membrane
of the RBCs, which is directly related to MNPs size,
shape and composition. The proposed microfluidic
tool adds a new dimension into the field of
nanomedicine, allowing to be applied as a high-
sensitivity technique capable of bringing a better
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understanding of the biological impact of nanoparti-
cles developed for clinical applications.
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Introduction
Iron oxide nanoparticles have attracted much attention
in the last decades, especially for biomedical applica-
tions, due to their remarkable physicochemical prop-
erties acquired at the nanoscale. Superparamagnetism,
high surface-to-volume ratio, high field irreversibility,
high saturation magnetization, extra anisotropy con-
tributions, biocompatibility and non-toxicity are some
of these properties (Hervault and Thanh 2014; Rivas
et al. 2012). Particularly, the possibility to be chem-
ically functionalized with specific biocompatible tar-
geting molecules provides them with the ability to
selectively attach to cells or tissues. In addition,
magnetic nanoparticles (MNPs) can be simultaneously
used as contrast agents for magnetic resonance
imaging (MRI) and for tumour therapy (i.e. magnetic
hyperthermia and/or drug delivery), combining ther-
apeutics and diagnosis, the so-called theranostics
(Hervault and Thanh 2014). This combination is
especially useful due to the enhanced permeability
and retention effect (known as EPR effect), consisting
of a selective accumulation of nanoparticles near the
tumour tissues, normally surrounded by a high con-
centration of irregular and leaky blood vessels, and
allowing the improvement of cancer diagnostic and
specific treatments (Gallo et al. 2013).
Magnetic fluid hyperthermia (MFH) is considered a
promising therapeutic technique for cancer treatment
since it implements the remarkable nanoscale physic-
ochemical properties of MNPs to generate heat under
an alternating magnetic field. These nanoheaters can
be designed to preserve healthy cells while destroying
selectively tumoral cells, inherently more sensitive to
mild temperature changes of 5–7 C above the body
temperature (Jordan et al. 1999). Nevertheless, to get
the desired therapeutic effect, MFH needs to fulfil
several requirements that should be suitably balanced;
MNPs should be designed small enough (i) to be able
to cross the blood barrier and to penetrate into the
tumour; (ii) to escape from the mononuclear phago-
cyte system (MPS) providing an enhanced blood
circulation half-life; (iii) to have low sedimentation
rates (i.e. high stability in suspension); and (iv) to
show a good tissular diffusion (Mahmoudi et al. 2011;
Rivas et al. 2012). Additionally, after the removal of
the external magnetic field they should no longer show
magnetization (negligible remanence and coercivity)
to prevent their aggregation or the formation of clots in
the blood circulation system (Ban˜obre-Lo´pez et al.
2013; Obaidat et al. 2015). However, the reduction of
theMNPs size is directly related to the reduction of the
saturation magnetization (Ms) and, therefore, to the
decrease of their heating efficiency (Ban˜obre-Lo´pez
et al. 2013; Deatsch and Evans 2014). In this context, a
major concern in nanoparticle synthesis for biomed-
ical applications is nanosize control and its manipu-
lation changing synthetic parameters, such as pH,
temperature, ion species ratio and ionic strength,
among others (Baumgartner et al. 2013; Hao et al.
2010). Despite the large number of reports on the
development of MNPs for theranostic applications
(Baumgartner et al. 2013; De Haas-Kock et al. 2009;
Hayashi et al. 2013; Hocaoglu et al. 2015; Mahmoudi
et al. 2011; Szekeres et al. 2015; Wang et al. 2015;
Zavisova et al. 2015), just a few of them report
biocompatibility studies of these MNPs (Grudzinski
et al. 2013; Hocaoglu et al. 2015; Wang et al. 2015;
Zavisova et al. 2015) and even less report their
haemocompatibility (Hocaoglu et al. 2015; Wang
et al. 2015). In fact, haemocompatibility determina-
tion is crucial to understand the real in vivo potential
of any material envisioned for systemic administra-
tion, due to potential toxicological reactions (e.g.
embolization, haemolysis and coagulation). In addi-
tion, haemocompatibility studies have been shown to
be more sensitive than animal cell toxicity assays
(Hocaoglu et al. 2015). Nevertheless, there is a lack of
reports regarding the complex nanoparticle-RBCs
membrane interaction, especially due to the small
size of the nanoparticles, which makes very challeng-
ing to explore, even in vitro, the haemodynamic and
the complex vascular environment (Tan et al. 2012). In
this way, this paper presents for the first time a
microfluidic tool based on a constriction channel
capable of evaluating, in mimicked environments
(close to in vivo microvessels), the biocompatibility
and toxicity impact that biomedical-oriented MNPs
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present on human blood cells. Combining this
microfluidic tool with a high-speed video microscopy
system, multiple parameters (i.e. transit time, recovery
time and cell deformability) that cannot be assessed
via conventional approaches can be quantified with
great detail. In the past, the first constriction channel-
based microfluidic geometries were generally based
on sudden and narrow channels, which were adopted
to determine the rheological and hydrodynamic effect
of these structures over the elasticity and deformation
of the RBCs. Hence, it was observed that these
constriction geometries had the ability to characterize
the influence of possible diseases in the blood cells by
determining differences in their natural deformations
index (DI) (Abkarian et al. 2008). However, it was
found that these close-fitting geometries in the form of
long constrictions, which allow the uniaxial exten-
sional motion and stretching of healthy blood cell
along the flow direction, also promote the clogging of
the channel when the blood cells increase their rigidity
(Abkarian et al. 2008). To overcome this drawback,
microfluidic devices with a hyperbolic channel based
on extensional flow approach were adopted with great
success by Lee et al. (2009), Yaginuma et al. (2013)
and Faustino et al. (2014). In these pioneering works,
the mechanical, rheological and haemodynamic envi-
ronment created by the hyperbolic-shaped contrac-
tions were exhaustively tested, allowing to conclude
that hyperbolic converging microchannel is a more
accurate technique to determine the DIs of the flowing
RBCs than shear flow-based methodologies. More-
over, it was demonstrated that the deformability of
blood cells could be detailed and quantitatively
described under a controlled homogeneous exten-
sional flow, without the cell’s tumbling and rotational
motions usually observed in the shear flow-based
methodologies (Lee et al. 2009; Oliveira et al. 2007;
Yaginuma et al. 2013). Hence, this microfluidic
methodology has proven to be the most adequate
technique to gain insights into the DIs of RBCs as
natural biomarkers to identify many pathologies (e.g.
as malaria (Suwanarusk et al. 2004), diabetes (Sabo
et al. 1993), coronary diseases (Yaylali et al. 2013),
among others).
In line with aforementioned studies, the overriding
aims of the present work are (1) the development of
MNPs suitable for the diagnosis and treatment of
cancer; (2) the determination of the haemocompati-
bility of the designed MNPs using a conventional
analysis technique (i.e. haemolysis test); (3) the
application of a microfluidic tool capable of bringing
a new concept to assess with high accuracy the
haemocompatibility and toxicity effect of MNPs
developed for theranostic applications (i.e. hyperther-
mia, contrast enhancement agent for MRI, drug
delivery systems, etc.). Moreover, and to best of our
knowledge, this is the first time that an experimental
microfluidic methodology is tested with the purpose of
gaining new insights over the complex nanoparticle–
RBCs membrane interaction, mimicking micro-rheo-




Ammonium hydroxide solution (NH4OH, 25 wt % in
H2O) was purchased from Merck (NJ, USA). Iron (II)
chloride tetrahydrate (FeCl24H2O, 99 %), Dextran 40
((C6H10O5)n) and ethanol absolute (C2H6O, 99.8 %)
were purchased from Sigma-Aldrich (MO, USA). Iron
(III) chloride hexahydrate (FeCl36H2O, 97 %) was
supplied by Panreac (Barcelona, Spain). Alendronic
acid and acetone were purchased from TCI Europe.
Physiological salt solution (PSS) with 0.9 %NaCl was
supplied by B. Braun Medical (Germany). All chem-
icals were of analytical grade and used as received
without further purification. All aqueous solutions
were prepared in deionized water.
Synthesis of magnetic nanoparticles (MNPs)
Briefly, FeCl36H2O (134 mM), FeCl24H2O
(67 mM) and NH4OH (1 M) solutions were prepared
in deionized water at room temperature. Two samples
of magnetite were synthesized by alkaline co-precip-
itation, mixing in 100 mL of deionized water the iron
precursors in the stoichiometric ratio 1:2 of iron (II)
and iron (III) salts under vigorous magnetic stirring
(C-Mag HS7, IKA) and heating the resultant mixture
until the desired temperature (30 and 55 C). Then, the
basic NH4OH (1 M) solution was added dropwise
until pH *9, promoting the co-precipitation of the
magnetite nanoparticles. The black solution formed in
this process was maintained for 30 min at the same
temperature and stirring conditions, ensuring the
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complete magnetite crystal formation. After that, the
MNPs samples were subjected to repeated washing
steps in deionized water to remove impurities; the last
washing step was carried out with absolute ethanol and
the final particles were dried at 60 C overnight. The
resulting materials were labelled as MAG30 and
MAG55 depending on the used heating temperature
(30 or 55 C, respectively).
The colloidal stabilization of the ferrofluids is one of
the most critical parameters to perform an accurate
evaluation of the designed magnetic nanoparticles for
theranostic applications (Ruiz et al. 2014). In general,
the synthesized magnetic nanoparticles suffer from
their strong high surface energy and hydrophobicity
interactions, causing their agglomeration and fast
sedimentation in the presence of an aqueous carrier
fluid. In this sense, the functionalization of the
developed magnetic nanoparticles with hydrophilic
ligands represents a fundamental post-synthetic step
for the further evaluation of themagnetic nanoparticles
designed for theranostic applications. In this study,
hydrophilic MNPs ferrofluids were obtained after
addition of a solution of alendronic acid (Al, 50 mM,
pH 10) into the colloidal suspensions of MAG30 or
MAG55 (1 mg/mL), using a ratio 4:1 (v/v). The
mixtures were sonicated during 15 min and vigorously
stirred for 48 h at room temperature. These resulting
suspensions were centrifuged at 6000 rpm for 5 min
(Allegra 64R, Beckman Coulter) and washed with
acetone to remove free alendronate from the coated
MNPs. The purification procedure was repeated twice.
The resulting MNPs@Al (MAG30@Al and
MAG55@Al) were dispersed in water, sonicated for
30 s and stored at room temperature.
Characterization of magnetic nanoparticles
Size, crystal structure and chemical composition
Transmission electron microscopy (TEM, LEO/ZEISS
906E) was used to analyse individually the morphology
and particle size distribution, MAG30 and MAG55,
employing an ImageJ software (1.46r, NIH). For each
sample, 120 individualMNPs were randomlymeasured
and the results shown asmean. The crystalline phases of
these materials were analysed by X-ray diffraction
(XRD) in a PAN’alyticalX’Pert PROequipment (CuKa
radiation) equipped with X’Celerator detector and
secondary monochromator, in h/2h geometry. The
diffractograms were analysed by Rietveld refinement
using PowderCell software. Crystallite sizes were
calculated applying Williamson-Hall model to refine-
ment results. An inductively coupled plasma-optical
emission spectrometer (ICP-OES, ICPE-9000, Shi-
madzu) was employed to determine the iron content
on the MNPs@Al hydrophilic samples.
Magnetic and hyperthermia properties
The magnetic properties of the powder samples,
MAG30 and MAG55, were investigated with a super-
conducting quantum interference device (SQUID-
VSM) magnetometer from Quantum Design. Hystere-
sis curves were recorded for magnetic fields between
-20 kOe and ?20 kOe at room temperature (300 K).
The temperature-dependent magnetization was
recorded under a magnetic field of 50 Oe in the
temperature range between 2 and 300 K, in both zero-
field-cooled (ZFC) and field-cooled (FC) samples. The
MNPs@Al heating efficiencies were evaluated in a
hyperthermia equipment (DM 100 system, nB nanos-
cale Biomagnetics) using 1 mL of MNPs@Al water
dispersion (0.4 g (Fe3O4)/L) under an applied oscil-
lating magnetic field of 15.95 kA/m at a resonant
frequency of 688 kHz. The temperature increase was
measured with an optical fibre and recorded as a
function of the time for 10 min.
Magnetic resonance relaxivity studies
The MRI contrast enhancement efficiency of
MNPs@Al was studied by the determination of the
T1 (longitudinal) and T2 (transversal) relaxation times
with a fixed field relaxometer (Minispec NMR spec-
trometer mq60, Bruker Instruments) at a magnetic
field strength of 1.41 T. To this purpose, three different
Fe concentrated solutions were prepared of each
sample (MAG30@Al and MAG55@Al), with Fe
concentrations of 0.00, 0.04, and 0.08 mM. The r1
and r2 relaxivities were determined from the slopes of
a linear fitting of 1/T1 or 1/T2 versus the Fe content of
the samples.
Haemolysis analysis
Haemolysis induced by nanoparticles treatment was
assessed photometrically by a UV–Vis spectropho-
tometer (T70 spectrometer, PG Instruments Ltd.).
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Human whole blood from healthy donors were
collected into 2.7 mL tubes (S-Monovette, Sarstedt)
containing ethylenediaminetetraacetic acid (EDTA),
followed by dilution in a ratio 1:4 (v/v) in PSS.
MNPs@Al were further suspended in the diluted
whole blood to obtain a final concentration of 17.4 and
34.8 lg (Fe3O4)/mL. Positive control was obtained
using the whole blood diluted in a ratio 1:4 (v/v) in
PSS buffer and the negative control by adding to the
diluted whole blood the same volume of deionized
water (1:1, v/v). The solutions with MNPs@Al and
controls were incubated at 37 C during 1 h in a
shaking water bath. The released haemoglobin was
determined after centrifugation at 3000 rpm for 5 min,
followed by photometric analysis of the supernatant at
540 nm. The haemolysis ratio (HR) was calculated
from the optical density (OD) using Eq. (1) (Wang
et al. 2015).
HR %ð Þ¼ð100ðODtest sampleODnegative controlÞÞ=
ðODpositive controlODnegative controlÞ ð1Þ
The data were calculated from three independent
experiments (mean ± standard deviation).
Microfluidic studies
Microfluidic device, experimental setup
and parameters
The polydimethylsiloxane (PDMS) microchannels
evaluated in this work were fabricated using a soft-
lithographic technique, as previously reported by
Lima et al. (2008). Figure 1 shows the main channel
of the microfluidic device that was designed to have
the following dimensions: 20 9 400 9 26,389 lm
(height 9 width 9 length).
Furthermore, in the centre of this main channel, a
hyperbolic-shaped contraction with a Hencky strain of
*3 (also called as logarithmic strain, eH = ln (Ww/Wn)
(Oliveira et al. 2007)), was designed to have the
following dimensions: 400 lm of length and widths of
400 and 20 lm, respectively, at the wide (Ww) and
narrow sizes (Wn). As a consequence, the high Hencky
strain imposed on this geometry allows an almost linear
velocity increase with the axial position, x, without
suffering entrance or exit effects (Oliveira et al. 2007).
The microscopy system used in this work consisted
on an inverted microscope (IX71, Olympus) combined
with a high-speed camera (Fastcam SA3, Photron,
USA). In the inverted microscope, the PDMS
microchannel was placed and fixed, and the flow rate
of the working fluids kept constant at 5 lL/min by
means of a syringe pump (PHD Ultra, Harvard
Apparatus, USA) with a 2 mL syringe (Terumo,
Japan). At the same time, the images of the flowing
blood cells, at the established flow rate, were captured
by the high-speed camera with a frame rate of 2000
frames/s and a shutter speed ratio of 1/75,000. These
capture parameters allowed the minimization of cells
dragging caused by the high flow rate.
Table 1 shows the experimental parameters used to
perform the haemodynamic study of RBCs as natural
biophysical markers to evaluate the MNPs biocom-
patibility, by assessing their DIs in the described
hyperbolic channel.
Fig. 1 Microfluidic device
fabricated in PDMS with a
hyperbolic-shaped
contraction to assess the
haemocompatibility of the
RBCs in contact with MNPs
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Working fluid protocol
A Dextran 40 solution (10 %, w/v) containing 2 % of
haematocrit (RBCs, v/v) was used as the working fluid
to perform the deformability tests in the microfluidic
devices. The amount of MNPs@Al was studied at 0.0,
17.4 and 34.8 lg (Fe3O4)/mL. The working fluid
prepared without MNPs@Al (0.0 lg (Fe3O4)/mL)
was used as positive control.
Briefly, venous human blood samples from healthy
donors were collected into 2.7 mL tubes (S-
Monovette, Sarstedt) containing EDTA to avoid
coagulation, and centrifuged at 2500 rpm for 10 min
at 4 C. The buffy coat and plasma were removed and
the packed RBCs re-suspended and washed twice in
PSS with 0.9 % NaCl, in a ratio 1:1 (v/v). The final
working fluid was prepared immediately before the
experiments by mixing together the collected RBCs
with the desired amount of MNPs@Al in the Dextran
40 solution (10 %, w/v). Dextran 40 solution was used
as carrier fluid instead of the blood plasma to avoid the
clotting and jamming of the blood cells in the in vitro
microfluidic studies, which are generally promoted by
some components, i.e. immunoglobulins, clotting
factor, albumin and fibrinogen proteins. The working
fluid samples were incubated at 37 C during 15, 30,
and 60 min in a shaking water bath, allowing the
evaluation of the time-contact effect between the
MNPs and the deformability of RBCs.
Image analysis
The experimental images recorded in each test were
transferred to a computer, processed and analysed by
an image handling software, ImageJ (1.46r, NIH,
USA). Using this software, DI of the blood cells was
calculated as previously reported by Pinho et al.
(2013), using Eq. (2) (Yaginuma et al. 2013):
DI ¼ Lmajor  Lminor=Lmajor þ Lminor ð2Þ
For each deformability test performed with three
amounts of MNP@Al (0.0, 17.4 and 34.8 lg (Fe3O4)/
mL), the DI of 112 red blood cells in two independent
experiments was assessed along the microfluidic
channel with a hyperbolic-shaped contraction fol-
lowed by a sudden expansion.
Statistical analysis
The microfluidic results were displayed as mean ± s-
tandard deviation using two independent experiments
(n = 112 red blood cells). The statistical analysis was
performed with the Student’s t test for one-tailed
distribution with a significance level of p\ 0.05,
represented as asterisks (*) in comparison with the
control test. All statistical analyses were performed
using Microsoft Office Excel (version Professional
Plus 2013).
Table 1 Experimental
parameters used to perform







Maximum width of the microchannel 400 lm
Minimum width of the microchannel 20 lm
Total length of the contraction region 400 lm
Depth of the microchannel 20 lm
Inlet flow rate 5 lL min–1
Mean velocity of the fluid 5.21 mm s–1
Mean diameter of the human RBC at rest 8 lm
Shear viscosity of the Dextran 40 4.5 9 10-3 Pa s–1
Density of the Dextran 40 1046 kg m–3
Haematocrit of the working fluid 2 %
MNPs concentration 17.4 and 34.8 lg Magnetite/mL
Temperature of the working fluid 37 C
Magnification (M) 20 9 (optical zoom 1.69)
Frame rate 2000 frames s-1
Exposure time 500 ls
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Ethical approval
Ethical approval was given by the medical ethics
committee of the Unidade Local de Sau´de do
Nordeste, E.P.E. (Braganc¸a, Portugal).
Results and discussion
Characterization of the developed MNPs
Size, crystal structure and chemical composition
The results obtained by TEM analysis of MAG30
and MAG55 are shown in Fig. 2, revealing that the
magnetic core of the synthesized nanoparticles is
nearly spherical for both samples. Nevertheless, the
increase of the synthesis temperature leads to a
growth in the average diameter of the magnetic
core, from 11.1 (MAG30) to 17.7 nm (MAG55),
which is in good agreement with the crystallite sizes
obtained by the XRD analysis (Table 2), as expected
for particle sizes within the single-domain super-
paramagnetic region.
Additionally, the determination of the nanoparticle
size distribution reveals that not only the average
nanoparticle diameter grows as synthesis temperature
increases, but also the nanoparticle size polydisper-
sion. Nevertheless, for the higher synthesis tempera-
ture used in this study (55 C), none of the measured
MNPs was found to be larger than 50 nm.
All the reflection peaks of the XRD patterns of
MAG30 and MAG55 were indexed by considering a
magnetite phase. No reflections peaks were observed
as impurities or secondary phases. The cubic cell
lattice parameter resulted to be a *8.37 A˚, in good
agreement with the values reported for nanosized
magnetite (Aphesteguy et al. 2015). Also, Table 2
shows the crystallite size, which was calculated from
the 5 most intense peaks of the XRD patterns through
the Williamson–Hall formula (Khorsand et al. 2011).
For comparison reasons, the particle diameter
observed by TEM is also shown that resulted to be
very similar to that obtained from the XRD data, as
expected for particle sizes within the single-domain
superparamagnetic region. Thus, these results enable
the co-precipitation method under mild experimental
conditions, as a suitable synthesis method to ensure the
Fig. 2 Histogram and mean diameter (X) of the nanoparticles following the Log-normal distribution of aMAG30 and bMAG55. Inset
shows the corresponding TEM images
Table 2 Physico-chemical properties of the synthesized nanoparticles: diameter determined by TEM (dTEM), crystallite size cal-
culated from XRD (dhkl), lattice constant and crystalline core phase obtained by XRD analysis
Sample Synthesis method dTEM (nm)
a dhkl (nm)
b Lattice constant, a (A˚) Crystalline core phases, % (v/v)
MAG30 Co-precipitation, 30 C 11.1 12.8 8.3652 100 % Magnetite (Fe3O4)
MAG55 Co-precipitation, 55 C 17.7 18.5 8.3653 100 % Magnetite (Fe3O4)
a Estimated using ImageJ software as mean (n = 120)
b Calculated using the Williamson–Hall equation (Khorsand et al. 2011)
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presence of a single-phase (magnetite), which is ideal
for biomedical applications.
Magnetic and hyperthermia properties
The main magnetic parameters of MAG30 and
MAG55, namely saturation magnetization, coercivity
and remanence, were calculated from the analysis of
the magnetization curves as a function of the applied
magnetic field obtained for powdered samples (see
Table 3; Fig. 3). The specific absorption rate (SAR,
W/g (Fe3O4)) values were calculated according to
Eq. (3) (Szekeres et al. 2015):
SAR ¼ ðCmwater=mFe3O4ÞðDT=DtÞ ð3Þ
where C is the specific heat capacity of the medium
(Cwater = 4.186 J g
-1 C-1), mwater and mFe3O4 are
the masses of the medium and magnetite, respectively,
and DT/Dt is the initial temperature rate. In addition,
the intrinsic loss power (ILP), independent of the
magnetic field amplitude and frequency used in the
experiment and that allows for a direct comparison
between different reported values, was calculated
using Eq. (4) (Kolen’ko et al. 2014):
ILP ¼ SAR=H2f ð4Þ
where SAR is the specific absorption rate given by
Eq. (3), H is the field amplitude and f is the frequency
used in the hyperthermia experimental setup.
Both MAG30 and MAG55 hysteresis loops show a
superparamagnetic-like behaviour. Whereas MAG30
(11.1 nm of particle size) showed a saturation mag-
netization, Ms, of 56 emu/g, the increase of the
synthesis temperature in MAG55 led to an increase
of the particle size (17.7 nm) that subsequently
resulted in an increase of Ms, which is near to the
bulk value of magnetite, i.e. 90 emu/g (Lu et al. 2007).
Nevertheless, MAG55 exhibits lower remanence (Mr)
and coercive forces (Hc) at room temperature com-
pared toMAG30, despite the higher particle size of the
individual particles (see Table 2). This unlike result
has been previously reported (Kolen’ko et al. 2014),
and explained to be caused by the effect of the dipolar
magnetic interactions caused by the presence of
clustering in small nanoparticles.
On the other hand, the zero-field-cooling–field-
cooling (ZFC–FC) magnetization curves shown in
Fig. 3 indicate a shift of the blocking temperature
(TB), defined as the temperature above which the
MNPs show superparamagnetic behaviour (Obaidat
et al. 2015), from 175 to 300 K (or higher) for MAG30
Table 3 Magnetic properties of the Fe3O4 nanoparticles synthesized by co-precipitation at different synthesis temperatures (30 and
55 C): saturation magnetization (Ms), coercivity (Hc), saturation remanence (Mr), SAR and ILP
Sample Ms (emu/g Fe3O4 ) Hc (Oe) Mr (emu/g Fe3O4 ) SAR
a (W/g Fe3O4 ) ILP
b (nHm2/kg)
MAG30 56.19 ± 0.02 33.65 3.77 100.18 0.57
MAG55 77.68 ± 0.03 18.33 1.94 565.68 3.23
a Specific absorption rate (SAR) calculated for H = 15.95 kA/m, f = 688 kHz, C = 0.40 g (Fe3O4)/L




and MAG55. a Hysteresis
loops at room temperature
(300 K) up to ± 20 kOe; the
inset is a zoom in the low-
field region; b ZFC–FC
magnetization curves
measured at 50 Oe
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and MAG55, respectively. In both cases, the flatness
of the FC curve below TB is indicative of significantly
strong dipolar magnetic particle interactions. Hence,
the confirmation of a superparamagnetic state for both
MAG30 and MAG55 at room temperature makes
these samples suitable for MRI and hyperthermia
applications.
The hyperthermia performance ofMAG30@Al and
MAG55@Al nanoparticles was determined in water
solution at a concentration of 0.40 g (Fe3O4)/L. Both
nanoparticle dispersions were evaluated in terms of
specific absorption rate (SAR) and independent loss
power (ILP), which are shown in Table 3. Figure 4
shows the temperature profiles as a function of time for
both samples under the same hyperthermia conditions
(H = 15.95 kA/m; f = 688 kHz).
As expected, SAR increases with increasing size of
the magnetic core of the iron oxide nanoparticles.
Indeed, many works compiled by Deatsch and co-
workers in 2014, pointed to the optimal diameter for
magnetite nanoparticles be applied in magnetic hyper-
thermia, fall somewhere between 12 and 20 nm.
However, the comparison between different studies
is very difficult since SAR results strongly depend on
the magnitude and frequency of the applied magnetic
field. Thus, to overcome this issue, ILP was proposed
as a measure of heating efficiency that normalizes
SAR with respect to field strength, H, and frequency,
f. ILP results revealed a remarkable heating efficiency
for the MAG55 nanoparticles (3.23 nHm2/kg) when
compared with ILP values found for coated magnetite
(e.g. mPEGs, Chitosan, 2,3-Dimercaptosuccinic acid,
(3-Amino-propyl)triethoxysilane, Dextran, among
others) (Hervault and Thanh 2014; Sharifi et al.
2012), or even reported commercial ferrofluids, which
are in the range 0.20–3.10 nHm2/kg (Presa et al. 2012).
In fact, it should be noted that the hyperthermia tests
performed in this work were made with an extremely
low concentration of colloidal suspension (0.40 g
(Fe3O4)/L), which is at least 10 times lower than the
typical values used in other published magnetic
hyperthermia tests (Presa et al. 2012; Szekeres et al.
2015). Nevertheless, the sample MAG55@Al showed
a temperature increment of 12 C, after 10 min of
exposure to the applied magnetic field. Thus, the
derived good ILP result obtained for MAG55@Al is
likely due to the combination of narrow size distribu-
tion of the synthesized MNPs, good colloidal stability
and strong magnetic response caused by the Ne´el and
Brownian power loss mechanisms, dominant and
comparable in superparamagnetic nanoparticles.
Magnetic resonance relaxivity studies
The contrast enhancement efficiency of MNPs@Al
was evaluated in water through relaxivity measure-
ments by plotting the relaxation rates (R1 = 1/T1 and
R2 = 1/T2) of water protons in the presence of the
nanoparticles, against the Fe content. Upon linear
fitting, the relaxivity values, r2 and r1, were obtained
from the respective slope and are listed in Table 4, as
well as the corresponding R2 of the linear fit, which
showed good fitting results.
Both MAG30@Al and MAG55@Al ferrofluidic
samples showed a similar r1 of*4 mM
-1 s-1, which
is higher than that of reported superparamagnetic iron
oxide nanoparticles (Szekeres et al. 2015). More
importantly, enhanced r2 values of 248.17 mM
-1 s-1
for MAG55@Al and 226.08 mM-1 s-1 for sample
MAG30@Al were achieved, which are in good
agreement with other results with surface modified
Fe3O4 nanoparticles (Barick et al. 2014), and far
superior than currently available intravenous iron
oxide nanoparticle contrast agents (Weinstein et al.
2010). Moreover, and as expected, these results
indicate that the relaxivity values r1 and r2 increase
with the MNPs growth, very likely due to the increase
in saturation magnetization.
In MRI, two main families of contrast agents can be
used, T1 or agents that affect mainly the longitudinal
relaxation (positive contrast, brightening of the
Fig. 4 Temperature versus time curves for MAG30@Al and
MAG55@Al water colloidal dispersions at 0.40 g (Fe3O4)/L,
under an oscillating magnetic field of 15.95 kA/m and 688 kHz
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image) and T2 or agents that have an effect predom-
inantly on the transverse relaxation (negative contrast,
darkening of the image) (Gallo et al. 2014). The r2/r1
ratio is considered a suitable indicator to assess the
efficiency of MNPs as a T1 or a T2 contrast agent. The
r2/r1 ratio of MAG30 and MAG55 resulted to be
higher than that of some commercial iron oxide
nanoparticles contrast agents (Saraswathy et al. 2014;
Weinstein et al. 2010), indicating that both samples are
promising candidates for high-efficiency T2-weighted
MR imaging.
Haemolysis analysis
Haemolysis analysis is one of the most common
studies performed to evaluate the haemocompatibility
of nanoparticles for biomedical applications (Lin et al.
2012; Wang et al. 2015), especially when they are
intended to be applied directly into the blood stream.
In fact, previous in vitro studies demonstrated that
several nanoparticles induced haemolysis, the extent
of the effect being directly related to particle size,
surface properties and experimental conditions (Lin
et al. 2012).
In the present study, two different contents of
MAG55@Al (the sample that shows better perfor-
mance in both MRI and MFH) were suspended in
diluted whole blood and tested, 17.4 and 34.8 lg
(Fe3O4)/mL. The selection of these concentrations was
based on the recommended dosage (15 lmol (Fe)/kg
of individual) for the commercial superparamagnetic
iron oxide-based MRI enhancer (ENDOREM, Guer-
bet S.A.) in individuals with a weight of 75 and
150 kg, respectively. This choice was made since
there are no guidelines available concerning the
optimal concentration of iron oxide nanoparticles to
be applied systemically for magnetic hyperthermia
treatment. Thus, the absorbance results of the super-
natant fluids, treated with different concentrations,
were compared and normalized with the result from
lysed RBCs in the presence of deionized water (taken
as 100 % lysed, negative control) and the blood in PSS
buffer without MNPs (taken as 0 % lysed, positive
control), using for this purpose Eq. (1).
According to the standard ISO 10993–4 for the
evaluation of biological medical devices suitable for
blood contact, thematerial shouldhavehaemolysis rates
lower than 5 % (Wang et al. 2015). In this work, the
haemolysis rateswere found to be lower than 2 % for all
tested concentrations.More precisely, it was found to be
1.08 ± 0.73 %, for a low content of nanoparticles
(17.4 lg (Fe3O4)/mL) and 1.63 ± 0.28 % for the
highest (34.8 lg (Fe3O4)/mL). Therefore, and accord-
ing to the guide for the evaluation of biological
materials, the synthesizedMNPs developed in this work
proved to fulfil the requirements of the haemolysis test
to be applied as medical materials for blood contact,
even at the highest concentration tested.
Microfluidic studies
In the literature, only a few studies can be found
reporting the influence of nanoparticles into the micro-
rheological properties of the human RBCs, or vice
versa, for biomedical application purposes (Mayer
et al. 2009; Mu¨ller et al. 2014; Thomas et al. 2014).
From those, some of them only report numerical
simulation results without comparison with experi-
mental tests (Mu¨ller et al. 2014; Thomas et al. 2014).
The main reason for this lack of in vitro studies may be
the mandatory requirement of multidisciplinary
research teams and high-tech laboratory facilities.
Nevertheless, to promote the application of multi-
functional nanomedicine based on nanoparticles,
many microfluidic, mechanistic and toxicological
milestones have to be accomplished in the near future.
Based on the expectation to provide mechanistic
insights on nanomedicines designed for theranostic
applications, a microfluidic tool was applied for the
first time to determine the impact of MNPs on the
Table 4 Longitudinal (r1) and transverse (r2) relaxivity of MAG30@Al and MAG50@Al. The corresponding coefficient of the
linear fit (R2) and relaxivity ratio (r2/r1) is also shown
Sample r2
a (mM-1 s-1) R2 (r2) r1
a (mM-1 s-1) R2 (r1) r2/r1
MAG30@Al 226.08 0.9986 4.02 0.9990 56.24
MAG55@Al 248.17 0.9992 4.42 0.9999 56.15
a Relaxivity values measured at B = 1.41 T and 37 C
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RBCs membranes (the major component of the blood
and the principal actor in micro-rheology).
The abnormal RBCs rigidity has been already
related to several diseases, pointing to the modification
of the membrane structural components (e.g. skeletal
filaments, transmembrane proteins and fatty acids)
(Kang et al. 2016; Zheng et al. 2012) and cytoplas-
matic content as the main reasons for this abnormal
rigidity change (Rodrigues et al. 2015). As a result,
rigid RBCs can cause phenomena of clotting in the
micro-circulatory vessels (namely, capillaries, arteri-
oles and venules), leading to the blocking of the
normal blood flow in microcirculation (Kang et al.
2016), which in the worst scenarios can cause
ischaemia in the tissues and/or lead to episodes of
cerebrovascular accidents (Yaginuma et al. 2013).
Hence, these blood cells have the potential to be used
as natural biophysical markers (Kang et al. 2016;
Zheng et al. 2012) without the costly labelling and
sample handling that is common for most biochemical
markers (Gossett et al. 2012). In this study, and for the
first time, a high-sensitivity microfluidic tool capable
to assess the deformability of blood cells was used to
evaluate the impact of nanoparticles on the human
RBCs. This methodology comprises a microfluidic
device having a hyperbolic-shaped contraction
microchannel and a high-speed video microscopy
system. This combined system enables the recording,
in real time, of the biomechanical microfluidic phe-
nomena, which can be then further analysed to obtain
valuable toxicological data.
Figure 5 shows a schematic view of the experi-
mental setup, the microfluidic device with the hyper-
bolic channel and the fluid-induced deformation
profiles occurring at the hyperbolic channel, making
this technique ideal for DI assessment.
Figure 5a represents the high-speed video micro-
scopy system used to perform the microfluidic studies.
Moreover, Fig. 5b, c shows the fluid-induced defor-
mation profiles that attest that the hyperbolic channel
approach is ideal for the assessment of the RBC’s DI.
As previously referred, this extensional flow technique
has already been shown to be more efficient in
deforming RBCs and assess their DI than other
techniques based on the shear flow (Lee et al. 2009;
Oliveira et al. 2007; Yaginuma et al. 2013). In this
sense, this extensional flow technique was used for the
first time as a microfluidic concept capable of gaining
new insights over the complex nanoparticle-RBCs
interaction designed for theranostic applications. The
main reason for this ability is the promotion of the
homogeneous extensional flow along the centreline of
Fig. 5 Microfluidic studies for the haemocompatibility of the
RBCs in contact with MNPs. a Schematic view of the
experimental setup; b Microchannel device geometry with the
zoom of the hyperbolic channel; c Graphical representation of
the fluid-induced condition profiles that occur in the hyperbolic
channel, which has proven to be a more efficient way for the
determination of the DI of the RBCs
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the hyperbolic channel with a high Hencky strain. In
this type of microfluidic devices, the velocity increases
almost linearly and the strain rate is maintained
approximately constant, even with the increment of
the shear rate (Oliveira et al. 2007). As a result, this
reported technique allows the deformation of the
blood cells along the microchannel, causing the RBC
stretching by the larger fluid shear stress, without
tumbling and rotational motions of the cells, providing
the most accurate way to determinate the DI of the
blood cells in mimic in vitro microvascular
environment.
Figure 6 shows a healthy RBC flowing along the
axial position, x, of the microchannel with a hyper-
bolic-shaped contraction followed by a sudden expan-
sion, which was subdivided into four sections to assess
the DI evolution of the RBCs along the microchannel.
Additionally, Fig. 6 shows the typical DI values found
for healthy RBCs when exposed to a hyperbolic
contraction (section 2, *0.50) followed by sudden
expansion region (section 4, *0.15), under a con-
trolled homogeneous extensional flow field (Lee et al.
2009; Yaginuma et al. 2013).
Using the set of data listed in Table 1, the DIs of the
RBCs (control versus MNPs) were measured flowing
along the centreline of the microchannel subdivided
into four sections (cf. Figure 6), and the results are
displayed in Fig. 7. Furthermore, to compare the
deformability behaviour of the tested samples, the
average shear rate and particle Reynolds number
(Rep), were calculated at four different sections as
shown in Fig. 6 and Table 5. The average or pseudo




where U is the mean velocity of the blood cells
obtained at each region and Dh is the hydraulic
diameter of each microchannel section (Mu¨ller et al.
2014). Additionally, the particle Reynolds number
(Rep) was defined as:
Rep ¼ qUDRBCl ð6Þ
where DRBC is the diameter of the human RBC at rest,
q is the density of the Dextran 40 solution and l is the
shear viscosity of the same solution (Yaginuma et al.
2013). Table 5 lists the mean ± standard deviation
values calculated for the Rep and average shear rate
along the microchannel.
The Rep is a useful tool to assess the behaviour of
the flowing cells suspended in the working fluid,
taking into account the inertial and viscous forces
that occur through the interactions of the blood cells
with the fluid. The results listed in Table 5 show that
this interaction is higher in the section 2, where the
average shear rate is also higher, and decreases in the
recuperation sections (sections 3 and 4), where the
average shear rate becomes lower. Note that in
microfluidic channels with a low aspect ratio (h/w,
where h refers to the depth (20 lm) and w refers to
the width (20–400 lm) of the microchannel), as
those presented in our study, the RBC deformability
is strongly affected by both extensional and shear
flow conditions. Moreover, since the shear stress is
usually reported in literature for the in vivo physi-
ological flow conditions, the average shear rate was
assessed and compared with values obtained in
human vascular systems (Sadler 1998; Vennemann
et al. 2007). In addition, the low standard deviation
obtained between all the samples along the
microchannel sections for the measured Rep shows
the maintenance of the same flow conditions in the
two independent microfluidic experiments, which is
crucial for the further comparison between the DI
results.
Fig. 6 Representation of a healthy RBC flowing along the axial
position of a microchannel with a hyperbolic-shaped contraction
followed by a sudden expansion, subdivided into four sections
with equal distances between them (125 lm). This approach
allows the assessment of the RBCs DIs, as an indicator of the
physiological effect of MNPs on the RBCs membranes.
Furthermore, the DI equation is represented, as well as the
typical values found for a healthy RBC subjected to a
hyperbolic-shaped contraction (section 2) and to a recuperation
section (section 4), under a controlled homogeneous exten-
sional flow field
 194 Page 12 of 17 J Nanopart Res  (2016) 18:194 
123
As expected, the maximum DI obtained with all
tested RBCs samples was measured in the hyperbolic
contraction region, where the width is minimum
(section 2, axial position 250 lm) and the average
shear rate is higher (*6000 s-1). Indeed, this value
of shear rate is very close to that of the arterioles in
Fig. 7 Deformation index of blood cell flowing along the axial
position of the hyperbolic channel, as well as the average shear
rate at each hyperbolic region. a Control RBCs versus RBCs in
contact with MNPs at a final concentration of 17.4 lg (Fe3O4)/
mL during 15, 30, and 60 min; b Control RBCs versus RBCs in
contact with MNPs at a final concentration of 34.8 lg (Fe3O4)/
mL during 15, 30, and 60 min. Error bars show the standard
deviation of two independent experiments (n = 112 blood
cells), and the asterisks (*) represent statistical significance in
comparison with control test for p\ 0.05 determined by
Student’s t test
J Nanopart Res  (2016) 18:194 Page 13 of 17  194 
123
the human vascular system (*8000 s-1) (Sadler
1998; Vennemann et al. 2007) and thus, ideal to test
the DI of RBCs at mimicked microvascular condi-
tions and to detect changes in the RBC DIs, as an
indicator of possible haematological disorders and
nanoparticle–cell interactions. Overall, the higher DI,
in section 2, was measured for the RBCs control (not
exposed to MNPs), reaching a maximum DI of
0.46 ± 0.02. It is worth mentioning that this result is
in good agreement with the results obtained by Lee
et al. (2009) for healthy RBCs submitted to higher
shear rates (0.42–0.60, for 0.6–9.0 Pa of extensional
stress). Nevertheless, the DI results for the RBC
samples in contact with MNPs show that the
incubation time and MNPs amount present in the
blood samples influence directly the maximum
deformability of those blood cells, as shown by the
statistical analysis in section 2 (maximum constric-
tion region) of Fig. 7a and b, where a significant
decrease of deformability in comparison with the
control test is observed. Hence, the DI results allow
to conclude that the increase of the incubation time
and the amount of MNPs lead to the decrease in DI
or, in other words, to the increase of rigidity of those
cells. This observation is even more obvious for the
sample with the higher content of MNPs and
exposure time (34.8 lg (Fe3O4)/mL, 60 min), where
the maximum DI detected (section 2) decreased to
0.32 ± 0.02, which is 1.44 times lower than the
control DI (0.46 ± 0.02). The rigidity promoted by
the MNPs into the RBC membranes is also observed
in the recuperation section (section 4, axial position
500 lm), where the average shear rate is minimum
(*241 s-1). In section 4, and comparing the results
obtained between the control sample and the RBCs
samples that were placed in contact with the MNPs,
it can be observed that RBCs incubated in the
presence of MNPs become more rigid than the
control RBCs, even when they are almost at rest. In
the latter case, the control RBCs had ellipsoid shapes
due to the applied shear flow, whereas RBCs in
contact with MNPs had geometries closer to a
circular shape which corresponds to the behaviour
of rigid cells.
Recently, Lin et al. (2012) were able to measure the
RBCs DI after the blood cells have been in contact
with nanodiamond nanoparticles at several shear
stress, using a laser aggregometer–deformometer
device. This study has shown that large nanoparticles
(100 nm average size) in contact with RBCs promote
the reduction of the RBCs deformability, or the
increase of their rigidity. Furthermore, using a confo-
cal microscope and observing the blood samples in
contact with the nanoparticles, the authors concluded
that large nanodiamonds were located around the
external environment of the RBCs, whereas smaller
nanodiamonds (5 nm average size) penetrated inside
the RBCs. As a result, it was established in this study
that the deformability of RBCs decreases significantly
for higher concentration of large nanodiamonds. This
effect was ascribed to changes in the membranes of
RBCs, probably caused by modifications in the
structure and activity of their proteins, which may
also lead to variations in the oxygenation–deoxygena-
tion dynamics. More recently, similar conclusions
were obtained by Curtis et al. (2015) through numer-
ical simulations with hydrophilic nanoparticles with
diameters ranging between 1 and 25 nm, in a bilayer
membrane (such as the RBCs membranes). The results
have shown that hydrophilic nanoparticles with
diameters greater than 2 nm become wrapped (the
lipids head groups of a membrane form a vesicle
around the nanoparticle), while smaller nanoparticles
became embedded in the bilayer surface, penetrating
into the membrane with minimal disruption to the
structure. Note that none of these studies can be
directly correlated with the deformability results
obtained in this work, and thus proving that the DI
changes observed are due to the MNPs wrap and
uptake by the blood cells membranes. This direct
correlation cannot be done since the size, shape and
composition also play an important role in this cellular
Table 5 Flow characteristics obtained for the four sections of the microchannel in the haemodynamic study
Flow characteristics Section 1 Section 2 Section 3 Section 4
Particle Reynolds number 0.08 ± 0.02 0.22 ± 0.02 0.04 ± 0.00 0.02 ± 0.01
Average shear rate (s-1) 1198.66 ± 83.82 5670.50 ± 731.29 483.35 ± 90.66 241.16 ± 65.97
Data represent mean ± standard deviation for two independent experiments (n = 112 blood cells)
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uptake. Therefore, further studies are required to
clarify the complex interaction MNPs–RBCs. How-
ever, these works highlight the accuracy of the
proposed microfluidic method, as a new and accurate
tool to investigate the haemocompatibility of MNPs,
where other more traditional analysis (such as
haemolysis tests) cannot show any specific alteration.
Conclusions
MNPs for theranostic applications were synthesized,
characterized and tested for magnetic hyperthermia
and MRI. The different heating behaviour of the
synthesized MNPs shows the importance of the
temperature as a synthesis parameter that allows the
growth of the magnetic core and subsequently allows
the increment of the saturation magnetization, while
the nanoparticle size remains in the single-domain
region with superparamagnetic behaviour. As a
result, the iron oxide nanoparticles were produced
through a cost efficient and industry friendly scalable
procedure, proven to be suitable for theranostics
application. Nevertheless, in order to be suitable for
biomedical applications, the synthesized MNPs
should be haematological safe. Thus, and since there
is a lack of studies in literature regarding this issue, a
high-sensitivity microfluidic tool was tested to gain
insights into the complex nanoparticle–RBCs mem-
brane interaction. This novel toxicological and
haematological concept was based on the proven
fact that the natural deformability of the RBCs can be
used as biophysical marker to assess haematological
pathologies or disorders. Hence, for the first time, it
is presented a microfluidic tool capable of evaluating
with high accuracy the impact of multifunctional
nanoparticles designed for theranostic applications in
contact with RBCs, using the proved extensional
flow approach to measure with high accuracy the
RBC’s DIs.
The traditional haematological test that was per-
formed in this work by the conventional haemolysis
analysis of the synthesised magnetic nanoparticles
with diameter around 18 nm suggests that these
nanoparticles are suitable for biomedical applications
in environment conditions, without showing almost no
haemolytic effect in the blood samples, even at the
higher content of nanoparticles tested (34.8 lg
(Fe3O4)/mL). On the other hand, the applied
microfluidic tool has shown that small MNPs can
influence the rigidity of RBCs in a time-dependent
manner, where other and more traditional biocompat-
ibility tests (such as the haemolysis analysis) did not
shown any influence. Moreover, it was demonstrated
that this influence is directly related to the concentra-
tion of MNPs within the working fluid. In fact, the
tested microfluidic tool has shown a higher sensitivity
to detect small changes in the RBC deformability,
which is unreachable using conventional techniques.
Due to this unique ability, this is the first experimental
test reported in the literature that subscribes the
numerical work performed by Curtis et al. (2015),
which points to the uptake of the surrounding MNPs
by the RBC membranes, as the main reason for the
increasing rigidity observed in the RBCs. In this recent
numerical study, it was also predicted a dependency
on the MNPs size, shape and composition with the
RBC membrane interaction.
It should be noticed that to gain a further under-
standing of the haemorheological and biological
interaction between MNPs and RBCs, other studies
should be performed to complement this one. Never-
theless, the presented haematological and toxicolog-
ical results confirm that it is highly desirable that blood
properties, including the effect of the MNPs on the
deformability of RBCs, and other rheological proper-
ties, should be controlled and tested together with the
traditional biocompatible tests. These new achieve-
ments and the effective understanding of the interac-
tion between MNPs and the blood cells will help to
promote the use of nanomedicine to the next level. For
instance, the MNPs–RBCs interactions revealed in
this study can be in the future investigated as a new
approach to deliver MNPs directly into the tumours,
using the RBCs as biocarriers that naturally escape
from the mononuclear phagocyte system. In fact, in a
very recent review performed by Villa et al. (2016),
they have shown the potentiality to use RBCs as
supercarriers for drugs, biologicals and nanoparticles
as advanced delivery systems. Hence, the proposed
microfluidic methodology represents a new concept
for the multidisciplinary nanomedicine field with
proven benefits to evaluate the haemocompatibility
of MNPs that are being developed for clinical
applications.
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